Your browser doesn't support javascript.
loading
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.
Romei, Cristina; Ciampi, Raffaele; Casella, Francesca; Tacito, Alessia; Torregrossa, Liborio; Ugolini, Clara; Basolo, Fulvio; Materazzi, Gabriele; Vitti, Paolo; Elisei, Rossella.
Afiliação
  • Romei C; Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Ciampi R; Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Casella F; Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Tacito A; Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Torregrossa L; Department of Surgical, Medical and Molecular Pathology, University Hospital of Pisa, Pisa, Italy.
  • Ugolini C; Department of Surgical, Medical and Molecular Pathology, University Hospital of Pisa, Pisa, Italy.
  • Basolo F; Department of Surgical, Medical and Molecular Pathology, University Hospital of Pisa, Pisa, Italy.
  • Materazzi G; Department of Surgical, Medical and Molecular Pathology, University Hospital of Pisa, Pisa, Italy.
  • Vitti P; Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Elisei R; Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Oncotarget ; 9(11): 9875-9884, 2018 Feb 09.
Article em En | PubMed-not-MEDLINE | ID: mdl-29515777
PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the corresponding metastatic tissues in a series of advanced metastatic cases. RESULTS: This study demonstrated that in about 20% of cases a different RET mutation profile can be found when comparing primary tumor and its corresponding metastases. Furthermore in 8% of tumors, RET intratumor heterogeneity was observed We also showed that in some cases an imbalance of RET copy number was present. We confirmed a high prevalence (90%) of RET somatic mutations in advanced tumors. MATERIALS AND METHODS: Fifty-six MTC patients (50 somatic and 6 hereditary cases) have been included in the study and a total of 209 specimens have been analysed by direct sequencing. Multiplex ligation-dependent probe amplification (MLPA) has been used to investigate amplification/deletion of RET alleles. CONCLUSIONS: In conclusion, this study showed a genetic intra- and intertumor heterogeneity in MTC, But in only 20% of CASES These results could justify the relatively moderate level of aggressiveness of the disease with respect to more aggressive human tumors that are characterized by a high rate of mutation and heterogeneity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália